Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment

American Journal of the Medical Sciences

Volumn 339, Issue 1, 2010, Pages 5-9

  Pawlak, Krystyna ^a   Buraczewska Buczko, Agnieszka ^a   Mysliwiec, Michal ^b   Pawlak, Dariusz ^a,c  

^a Department of Monitored Pharmacotherapy ^*  (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Cardiovascular disease; Chronic renal failure; Hyperfibrinolysis; Kynurenines; Oxidative stress

Indexed keywords

3 HYDROXYKYNURENINE; ANTIPLASMIN; COPPER ZINC SUPEROXIDE DISMUTASE; CREATININE; KYNURENINE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUINOLINIC ACID; TISSUE PLASMINOGEN ACTIVATOR; TRYPTOPHAN; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DRUG CONCENTRATION; FEMALE; FIBRINOLYSIS; GLOMERULUS FILTRATION RATE; HUMAN; INDEPENDENT VARIABLE; INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PREVALENCE; TRYPTOPHAN METABOLISM;

EID: 75449109806     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181b922a4     Document Type: Article

References (39)

1. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-636
2. Shlipak MG, Simon JA, Grady D, et al; Heart and Estrogen/ Progestin Replacement Study (HERS) Investigators. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001;38:705-711
3. Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int 2005;68:1413-1418
4. Foley RN, Parfrey P, Samak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32(suppl 3):S112-9. (Pubitemid 28527268)
5. Folsom AR, Aleksic N, Park E, et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001;21:611-617 (Pubitemid 32323396)
6. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999;82:259-270
7. Montes R, Paramo JA, Angles-Cano E, et al. Development and clinical application of a new ELISA assay to determine plasmin-alpha2- antiplasmin complexes in plasma. Br J Haematol 1996;92:979-985
8. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
9. Ito T, Niwa T, Matsui E. Fibrinolytic activity in renal disease. Clin Chim Acta 1972;36:145-151
10. Opatrny K Jr. Hemostasis disorders in chronic renal failure. Kidney Int Suppl 1997;62:S87-9.
11. Mezzano D, Tagle R, Panes O, et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996;76:312-321
12. Mezzano D, Pais EO, Aranda E, et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001;60:1844-1850
13. Mezzano D, Espana F, Panes O, et al. Increased activation of protein C, but lower plasma levels of free, activated protein C in uraemic patients: relationship with systemic inflammation and haemostatic activation. Br J Haematol 2001;113:905-910
14. Malyszko J, Malyszko JS, Mysliwiec M. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis. Kidney Blood Press Res 2004;27:71-77
15. Schroecksnadel K, Frick B, Winkler C, et al. Crucial role of interferon- gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006;4:205-213
16. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993;45:309-379
17. Okuda S, Nishiyama N, Saito H, et al. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 1998;70:299-307.
18. Pawlak K, Domaniewski T, Mysliwiec M, et al. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2009;204:309-314
19. Pawlak K, Brzosko S, Mysliwiec M, et al. Kynurenine, quinolinic acid-the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis 2009;204:561-566
20. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1):S1-266.
21. Pawlak D, Tankiewicz A, Mysliwiec P, et al. Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure. Nephron 2002;90:328-335
22. Pawlak K, Pawlak D, Mysliwiec M. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem 2005;38:700-705
23. Pawlak K, Pawlak D, Mysliwiec M. Oxidative stress effects fibrinolytic system in dialysis uraemic patients. Thromb Res 2006;117:517-522
24. Pawlak K, Pawlak D, Mysliwiec M. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. Thromb Res 2007;119:475-480
25. Chavakis T, Willuweit AK, Lupu F, et al. Release of soluble urokinase receptor from vascular cells. Thromb Haemost 2001;86:686-693
26. Mizukami IF, Faulkner NE, Gyetko MR, et al. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995;86:203-211
27. Dekkers PE, ten Hove T, te Velde AA, et al. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun 2000;68:2156-2160
28. Nykjaer A, Moller B, Todd RF III, et al. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 1994;152:505-516
29. Chavakis T, Kanse SM, Yutzy B, et al. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91:2305-2312
30. Pawlak K, Mysliwiec M, Pawlak D. Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure. Cytokine 2008;43:98-101.
31. Tanaka F, Ogura N, Abiko Y. Stimulation of plasminogen activator/ plasmin system in gingival fibroblast cells by oxygen radicals. Arch Oral Biol 1997;42:263-270
32. Besser D, Verde P, Nagamine Y, et al. Signal transduction and the u-PA/u-PAR system. Fibrinolysis 1996;10:214-237
33. Santamaria A, Salvatierra-Sanches R, Vazquez-Roman B, et al. Protective effects of the antioxidant selenium on quinolinic acidinduced neurotoxicity in rats: in vitro and in vivo studies. J Neurochem 2003;86:479-488
34. Sakkinen PA, Cushman M, Psaty BM, et al. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. Arterioscler Thromb Vasc Biol 1999;19:499-504.
35. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999;19:493-498
36. Morange PE, Bickel C, Nicaud V, et al; AtheroGene Investigators. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol 2006;26:2793-2799
37. Gyöngyösi M, Glogar D, Weidinger F, et al. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction. Am Heart J 2004;147:158-164
38. Pawlak K, Pawlak D, Mysliwiec M. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients. Thromb Res 2008;121:543-548 (Pubitemid 351174276)
39. Pawlak K, Pawlak D, Mysliwiec M. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients. Thromb Res 2007;120:871-876